Quarterly report pursuant to Section 13 or 15(d)

Asset Acquisition And License Agreements (Details)

v3.5.0.2
Asset Acquisition And License Agreements (Details) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 22, 2016
Sep. 30, 2016
Sep. 30, 2016
Dec. 31, 2015
Dec. 31, 2013
Merck | CERC-301          
Asset Acquisition And License Agreement [Line Items]          
Total Cost of License Agreement         $ 1,500,000
Other Commitment         750,000
Merck | CERC-301 | Research and development expense          
Asset Acquisition And License Agreement [Line Items]          
Initial license acquisition payments         750,000
Merck | COMT Inhibitor          
Asset Acquisition And License Agreement [Line Items]          
Initial license acquisition payments         $ 200,000
Lilly | CERC-611          
Asset Acquisition And License Agreement [Line Items]          
Initial license acquisition payments $ 2,000,000        
Upfront payment due within 30 days 750,000        
Upfront payment due after first subject dosed $ 1,250,000        
Lilly | CERC-611 | Research and development expense          
Asset Acquisition And License Agreement [Line Items]          
Initial license acquisition payments   $ 2,000,000 $ 2,000,000    
Lilly | CERC-501          
Asset Acquisition And License Agreement [Line Items]          
Term within execution of license agreement       30 days  
Other Commitment       $ 250,000  
Term of the study       9 months  
Lilly | CERC-501 | Research and development expense          
Asset Acquisition And License Agreement [Line Items]          
Initial license acquisition payments       $ 750,000